cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bladder Cancer
Details of phase III trial with Urocidin revealed for treatment of bladder cancer
December 14th, 2004
Bioniche Life Sciences, Inc., (BNC), a research-based, technology-driven Canadian biopharmaceutical company, announced details of its upcoming phase III clinical trial using its proprietary Mycobacterial Cell Wall-DNA Complex (MCC) - trademarked Urocidin - for the treatment of bladder cancer. This will be an international trial involving approximately 60 sites in North America and Europe. Alvaro Morales, professor of urology and oncology at Queen's University in Kingston, Ontario is the International Principal Investigator for the trial. At yesterday's Annual Meeting of Shareholders, Morales introduced the two other lead investigators: ...
Source: cancer weekly (2004-12-14)
|
